Amgen Inc (AMGN) 150.09 $AMGN
Go Back to the Future with These 5 Market Crushing Stocks
Eric Dutram - Zacks Investment Research - Wed Oct 21, 3:55PM CDT
If you ever have a time machine that can go back to 1985, you better buy these top performing stocks which have crushed the market over the past 30 years.
HD: 123.30 (+0.45), NKE: 132.47 (+0.10), AMGN: 150.09 (-0.36), MO: 59.84 (+0.10), AAPL: 113.76 (-0.01)
Kite (KITE) KTE-C19 Endorsed for EU Orphan Status Yet Again
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 3:35PM CDT
Kite Pharma (KITE) looks set to gain orphan drug status for KTE-C19 in the EU for three additional blood cancer indications.
BLUE: 80.78 (+0.15), KITE: 67.15 (+0.08), AMGN: 150.09 (-0.36), JUNO: 46.69 (-1.23)
Amgen Foundation Announces New $4 Million Commitment to Bring Hands-On Biotechnology Labs to Secondary School Students
PR Newswire - Wed Oct 21, 3:15PM CDT
The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States, Puerto Rico, United Kingdom and Ireland. The Amgen Biotech Experience includes an engaging series of labs that effectively bring biotechnology into classrooms. This new commitment will also strengthen the program's alignment with the United States' Next Generation Science Standards, which are focused on engaging students in more authentic science learning experiences. With the support of Education Development Center, Inc. (EDC), the global nonprofit leading the Amgen Biotech Experience Program Office, the investment is expected to empower 1,000 teachers who will reach more than 150,000 new students with the labs over the next two years.
AMGN: 150.09 (-0.36)
Biogen Tops Q3 Earnings, Announces Job Cuts, Ups View
Arpita Dutt - Zacks Investment Research - Wed Oct 21, 10:40AM CDT
Biogen (BIIB) surpassed Q3 earnings expectations by a wide margin.
BIIB: 276.34 (+10.53), AMGN: 150.09 (-0.36), AEGR: 14.98 (-0.56)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 276.34 (+10.53), HOG: 47.03 (-1.22), IBM: 140.92 (+0.28), GILD: 101.73 (+0.07), UTX: 97.97 (+2.35), PFE: 33.46 (-0.54), MRK: 50.59 (+0.20), AMGN: 150.09 (-0.36), VZ: 44.86 (-0.38), REGN: 518.53 (+3.86), TRV: 110.70 (+1.75), CELG: 115.92 (-0.32)
Illumina Tops Q3 Earnings, Meets Revenues; '15 View Cut
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 8:15AM CDT
Illumina's (ILMN) bottom line comfortably exceeded the Zacks Consensus Estimate, while the top line came in line with the same
AMGN: 150.09 (-0.36), ILMN: 140.17 (-4.93), ANIK: 34.28 (+0.11), NVET: 3.79 (-0.07)
New Tech Partnership Aims for Faster Rape Kit Processing
ACCESSWIRE - Tue Oct 20, 8:14AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 20, 2015 / Pressure BioSciences Inc. (OTCQB: PBIO), a developer and marketer of proprietary laboratory instrumentation and associated consumables to the $6 billion life sciences sample preparation market, aims to develop a rape kit test method based on its patented PCT Platform and launch it commercially within the next 18 months. With the potential to significantly speed up rape kit testing, the technology could help fill an enormous unmet need in the United States.
ENZ: 3.74 (-0.14), TMO: 127.11 (-1.51), NEO: 7.08 (+1.40), AMGN: 150.09 (-0.36)
Will Tecfidera Slowdown Hit Biogen (BIIB) Earnings in Q3?
Arpita Dutt - Zacks Investment Research - Mon Oct 19, 5:47PM CDT
Will Biogen (BIIB) miss third quarter expectations due to the slowdown in Tecfidera sales?
BIIB: 276.34 (+10.53), AMGN: 150.09 (-0.36), TEVA: 57.92 (+0.03)
After Yesterday's Rally of 1.22% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Oct 19, 3:57PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.46 to a high of $156.14. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $154.12 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 150.09 (-0.36)
Watch for Amgen to Potentially Pullback After Gaining 1.22% Yesterday
Comtex SmarTrend(R) - Mon Oct 19, 3:57PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.46 to a high of $156.14. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $154.12 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 150.09 (-0.36)
Is Lilly (LLY) Poised to Beat Earnings Expectations in Q3?
Arpita Dutt - Zacks Investment Research - Mon Oct 19, 3:26PM CDT
Will Lilly (LLY) succeed in surpassing earnings expectations on the back of strong diabetes and animal health segment sales?
AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), NVS: 91.59 (-0.74)
Zafgen Continues to Fall; Partial Clinical Hold on Beloranib
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 3:25PM CDT
Zafgen, Inc. (ZFGN) fell 50.7% after the company received a verbal notice from the FDA stating that beloranib has been placed on partial clinical hold.
ZFGN: 10.72 (-0.52), AMGN: 150.09 (-0.36), BMY: 62.51 (-1.38), ANIK: 34.28 (+0.11)
What's in Store for Morningstar (MORN) in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 2:35PM CDT
Morningstar Inc. (MORN) is set to report third-quarter 2015 results on Oct 21.
SKYW: 19.27 (+0.05), AMGN: 150.09 (-0.36), MORN: 81.98 (-1.64), ANIK: 34.28 (+0.11)
Will Currency Hit Abbott Laboratories (ABT) in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 1:50PM CDT
Abbott Laboratories (ABT) carrying a Zacks Rank #4 and an Earnings ESP of -1.83% is scheduled to report third-quarter 2015 results on Oct 21, 2015.
ABT: 42.20 (+0.46), AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), BMY: 62.51 (-1.38)
Will Hubbell (HUB-
Disappoint Earnings Estimates in Q3?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 12:25PM CDT
Hubbell Inc. (HUB- is set to report third-quarter 2015 results on Oct 22.
SKYW: 19.27 (+0.05), AMGN: 150.09 (-0.36), ANIK: 34.28 (+0.11), HUB.B: 87.44 (-0.78)
Johnson & Johnson: Stelara fares well in Crohn's disease
By LINDA A. JOHNSON - AP - Mon Oct 19, 9:40AM CDT
TRENTON, N.J. (AP) — Johnson & Johnson's immune disorder drug Stelara significantly reduced symptoms of the inflammatory bowel condition Crohn's disease with just one infusion in about half the patients tested, according to the company.
JNJ: 97.63 (+0.04), PFE: 33.46 (-0.54), AMGN: 150.09 (-0.36)
Texas Instruments (TXN) Q3 Earnings: What to Expect?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 9:10AM CDT
Texas Instruments Inc. (TXN)is set to report third-quarter 2015 results on Oct 21.
SKYW: 19.27 (+0.05), TXN: 51.90 (-0.53), AMGN: 150.09 (-0.36), ANIK: 34.28 (+0.11)
Eli Lilly's Failure Is a Success for These Companies
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 19, 6:42AM CDT
Image source: Eli Lilly. The mothballing of Eli Lilly 's once-promising next-generation cholesterol drug, evacetrapib, eliminates a potential competitor to Regeneron and Amgen 's recently launched cholesterol busters while also reducing...
ESPR: 22.51 (-0.29), AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), REGN: 518.53 (+3.86)
Go Back to the Future with These 5 Market Crushing Stocks
Eric Dutram - Zacks Investment Research - Wed Oct 21, 3:55PM CDT
If you ever have a time machine that can go back to 1985, you better buy these top performing stocks which have crushed the market over the past 30 years.
HD: 123.30 (+0.45), NKE: 132.47 (+0.10), AMGN: 150.09 (-0.36), MO: 59.84 (+0.10), AAPL: 113.76 (-0.01)
Kite (KITE) KTE-C19 Endorsed for EU Orphan Status Yet Again
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 3:35PM CDT
Kite Pharma (KITE) looks set to gain orphan drug status for KTE-C19 in the EU for three additional blood cancer indications.
BLUE: 80.78 (+0.15), KITE: 67.15 (+0.08), AMGN: 150.09 (-0.36), JUNO: 46.69 (-1.23)
Amgen Foundation Announces New $4 Million Commitment to Bring Hands-On Biotechnology Labs to Secondary School Students
PR Newswire - Wed Oct 21, 3:15PM CDT
The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States, Puerto Rico, United Kingdom and Ireland. The Amgen Biotech Experience includes an engaging series of labs that effectively bring biotechnology into classrooms. This new commitment will also strengthen the program's alignment with the United States' Next Generation Science Standards, which are focused on engaging students in more authentic science learning experiences. With the support of Education Development Center, Inc. (EDC), the global nonprofit leading the Amgen Biotech Experience Program Office, the investment is expected to empower 1,000 teachers who will reach more than 150,000 new students with the labs over the next two years.
AMGN: 150.09 (-0.36)
Biogen Tops Q3 Earnings, Announces Job Cuts, Ups View
Arpita Dutt - Zacks Investment Research - Wed Oct 21, 10:40AM CDT
Biogen (BIIB) surpassed Q3 earnings expectations by a wide margin.
BIIB: 276.34 (+10.53), AMGN: 150.09 (-0.36), AEGR: 14.98 (-0.56)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 276.34 (+10.53), HOG: 47.03 (-1.22), IBM: 140.92 (+0.28), GILD: 101.73 (+0.07), UTX: 97.97 (+2.35), PFE: 33.46 (-0.54), MRK: 50.59 (+0.20), AMGN: 150.09 (-0.36), VZ: 44.86 (-0.38), REGN: 518.53 (+3.86), TRV: 110.70 (+1.75), CELG: 115.92 (-0.32)
Illumina Tops Q3 Earnings, Meets Revenues; '15 View Cut
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 8:15AM CDT
Illumina's (ILMN) bottom line comfortably exceeded the Zacks Consensus Estimate, while the top line came in line with the same
AMGN: 150.09 (-0.36), ILMN: 140.17 (-4.93), ANIK: 34.28 (+0.11), NVET: 3.79 (-0.07)
New Tech Partnership Aims for Faster Rape Kit Processing
ACCESSWIRE - Tue Oct 20, 8:14AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 20, 2015 / Pressure BioSciences Inc. (OTCQB: PBIO), a developer and marketer of proprietary laboratory instrumentation and associated consumables to the $6 billion life sciences sample preparation market, aims to develop a rape kit test method based on its patented PCT Platform and launch it commercially within the next 18 months. With the potential to significantly speed up rape kit testing, the technology could help fill an enormous unmet need in the United States.
ENZ: 3.74 (-0.14), TMO: 127.11 (-1.51), NEO: 7.08 (+1.40), AMGN: 150.09 (-0.36)
Will Tecfidera Slowdown Hit Biogen (BIIB) Earnings in Q3?
Arpita Dutt - Zacks Investment Research - Mon Oct 19, 5:47PM CDT
Will Biogen (BIIB) miss third quarter expectations due to the slowdown in Tecfidera sales?
BIIB: 276.34 (+10.53), AMGN: 150.09 (-0.36), TEVA: 57.92 (+0.03)
After Yesterday's Rally of 1.22% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Oct 19, 3:57PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.46 to a high of $156.14. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $154.12 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 150.09 (-0.36)
Watch for Amgen to Potentially Pullback After Gaining 1.22% Yesterday
Comtex SmarTrend(R) - Mon Oct 19, 3:57PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.46 to a high of $156.14. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $154.12 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 150.09 (-0.36)
Is Lilly (LLY) Poised to Beat Earnings Expectations in Q3?
Arpita Dutt - Zacks Investment Research - Mon Oct 19, 3:26PM CDT
Will Lilly (LLY) succeed in surpassing earnings expectations on the back of strong diabetes and animal health segment sales?
AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), NVS: 91.59 (-0.74)
Zafgen Continues to Fall; Partial Clinical Hold on Beloranib
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 3:25PM CDT
Zafgen, Inc. (ZFGN) fell 50.7% after the company received a verbal notice from the FDA stating that beloranib has been placed on partial clinical hold.
ZFGN: 10.72 (-0.52), AMGN: 150.09 (-0.36), BMY: 62.51 (-1.38), ANIK: 34.28 (+0.11)
What's in Store for Morningstar (MORN) in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 2:35PM CDT
Morningstar Inc. (MORN) is set to report third-quarter 2015 results on Oct 21.
SKYW: 19.27 (+0.05), AMGN: 150.09 (-0.36), MORN: 81.98 (-1.64), ANIK: 34.28 (+0.11)
Will Currency Hit Abbott Laboratories (ABT) in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 1:50PM CDT
Abbott Laboratories (ABT) carrying a Zacks Rank #4 and an Earnings ESP of -1.83% is scheduled to report third-quarter 2015 results on Oct 21, 2015.
ABT: 42.20 (+0.46), AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), BMY: 62.51 (-1.38)
Will Hubbell (HUB-
Disappoint Earnings Estimates in Q3? Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 12:25PM CDT
Hubbell Inc. (HUB-
is set to report third-quarter 2015 results on Oct 22. SKYW: 19.27 (+0.05), AMGN: 150.09 (-0.36), ANIK: 34.28 (+0.11), HUB.B: 87.44 (-0.78)
Johnson & Johnson: Stelara fares well in Crohn's disease
By LINDA A. JOHNSON - AP - Mon Oct 19, 9:40AM CDT
TRENTON, N.J. (AP) — Johnson & Johnson's immune disorder drug Stelara significantly reduced symptoms of the inflammatory bowel condition Crohn's disease with just one infusion in about half the patients tested, according to the company.
JNJ: 97.63 (+0.04), PFE: 33.46 (-0.54), AMGN: 150.09 (-0.36)
Texas Instruments (TXN) Q3 Earnings: What to Expect?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 9:10AM CDT
Texas Instruments Inc. (TXN)is set to report third-quarter 2015 results on Oct 21.
SKYW: 19.27 (+0.05), TXN: 51.90 (-0.53), AMGN: 150.09 (-0.36), ANIK: 34.28 (+0.11)
Eli Lilly's Failure Is a Success for These Companies
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 19, 6:42AM CDT
Image source: Eli Lilly. The mothballing of Eli Lilly 's once-promising next-generation cholesterol drug, evacetrapib, eliminates a potential competitor to Regeneron and Amgen 's recently launched cholesterol busters while also reducing...
ESPR: 22.51 (-0.29), AMGN: 150.09 (-0.36), LLY: 77.01 (-0.78), REGN: 518.53 (+3.86)
